Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | GGT1 | P19440 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10676675 | 1.00 | DGAT1 (0.43) | DGAT1TDP1NR1H2GGT1MAOA | |
| SCHEMBL473483 | 1.00 | DGAT1 (0.43) | DGAT1TDP1NR1H2GGT1MAOA | |
| SCHEMBL4612473 | 0.83 | DGAT1 (0.33) | DGAT1TDP1 | |
| SCHEMBL12860069 | 0.81 | DGAT1 (0.48) | DGAT1TDP1GGT1MAOAMAOB | |
| SCHEMBL14485423 | 0.81 | DGAT1 (0.48) | DGAT1TDP1GGT1MAOAMAOB | |
| SCHEMBL14485421 | 0.81 | DGAT1 (0.48) | DGAT1TDP1GGT1MAOAMAOB | |
| SCHEMBL3383788 | 0.81 | DGAT1 (0.43) | DGAT1TDP1GGT1MAOAMAOB | |
| SCHEMBL27773297 | 0.81 | DGAT1 (0.43) | DGAT1TDP1NR1H2MAOAMAOB | |
| SCHEMBL25388987 | 0.79 | DGAT1 (0.41) | DGAT1TDP1NR1H2 | |
| SCHEMBL16065596 | 0.79 | DGAT1 (0.41) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105797168-A | Compositions and method for treatment of autoimmune and other diseases | 天蓝制药公司 | 2016-07-27 | — | — | CN | disclosed |
| US-8962622-B2 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC (US) | 2015-02-24 | — | — | US | disclosed |
| WO-2014012074-A2 | NO-RELEASING NONOATE (NITROGEN-BOUND) SULFONAMIDE-LINKED-COXIB ANTI-CANCER AGENTS | Euclises Pharmaceuticals, Inc. (US) | 2014-01-16 | — | — | WO | disclosed |
| CN-101511359-B | Benzotriazole kinase modulators | HOFFMANN LA ROCHE | 2012-09-05 | — | — | CN | disclosed |
| EP-2066319-B1 | BENZOTRIAZOLE KINASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2012-02-01 | — | — | EP | disclosed |
| CN-101511359-A | Benzotriazole kinase modulators | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | disclosed |
| US-20080103142-A1 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103142-A1 | Benzotriazole kinase modulators | CDK1, CDK3, MAPK1 | DGAT1 1563/4885TDP1 818/4885NR1H2 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.